州级丙型肝炎发病率及与注射吸毒者丙型肝炎预防和治疗服务相关政策——美国,2015-2016年
CDC评估美国各州关于安全注射器具获取的法律及医疗补助计划中与清醒要求相关的HCV治疗政策,并结合2015年急性HCV发病率进行分析。2015年HCV发病率仍高,17个州的发病率超过全国平均水平;仅3个州被判定具备全面预防和治疗注射吸毒者HCV的州法律和医疗补助政策。各州有机会采纳相关法律和政策以增加HCV预防和治疗服务的可及性。
要点
- 2015年美国HCV发病率仍高,17个州的发病率超过全国平均水平。
- 仅3个州被判定其州法律和医疗补助政策能全面预防和治疗注射吸毒者的HCV。
- 各州有机会采纳法律和政策以增加HCV预防和治疗服务的可及性。
核心结论
- 2015年美国HCV发病率仍高,17个州超过全国平均水平,仅3个州具备全面预防和治疗注射吸毒者HCV的州法律和医疗补助政策。
- 各州有机会采纳有助于增加HCV预防和治疗服务可及性的法律和政策,以减少HCV传播和疾病风险人群数量。
研究设计与样本
- CDC评估各州关于安全注射器具获取的法律以及医疗补助计划中与HCV治疗批准清醒要求相关的政策。
- 急性HCV发病率数据来自CDC的国家法定报告疾病监测系统(NNDSS)。
- 根据对清洁针具和注射器获取相关法律及医疗补助HCV治疗政策中清醒要求的分析,对各州进行分类。
主要发现
- 2015年美国HCV发病率仍高,17个州的发病率超过全国平均水平。
- 3个州被判定其州法律和医疗补助政策能够全面预防和治疗注射吸毒者的HCV。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatitis C is associated with more deaths in the United States than 60 other infectious diseases reported to CDC combined. Despite curative hepatitis C virus (HCV) therapies and known preventive measures to interrupt transmission, new HCV infections have increased in recent years (1,2). Injection drug use is the primary risk factor for new HCV infections (2). One potential strategy to decrease the prevalence of HCV is to create and strengthen public health laws and policies aimed specifically at reducing transmission risks among persons who inject drugs. To evaluate factors affecting access to HCV preventive and treatment services, CDC assessed state laws governing access to safe injection equipment and Medicaid policies related to sobriety requirements for approval of HCV treatment for persons who inject drugs. Acute HCV incidence rates were obtained from CDC's National Notifiable Disease Surveillance System (NNDSS). States were categorized based on analysis of laws related to access to clean needles and syringes and Medicaid HCV treatment policies associated with sobriety requirements. In 2015, HCV incidence remained high in the United States, with rates in 17 states exceeding the national average. Three states were determined to have state laws and Medicaid policies capable of comprehensively preventing and treating HCV among persons who inject drugs. Opportunities exist for states to adopt laws and policies that could help increase access to HCV preventive and treatment services reducing the number of persons at risk for HCV transmission and disease.
引用
- Campbell CA, Canary L, Smith N, et al. State HCV Incidence and Policies Related to HCV Preventive and Treatment Services for Persons Who Inject Drugs - United States, 2015-2016. MMWR Morb Mortal Wkly Rep. 2017. PMID: 28493854. doi:10.15585/mmwr.mm6618a2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。